We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple Blood Test Assesses Colon Cancer Risk

By LabMedica International staff writers
Posted on 06 Nov 2012
A novel blood test will help enable the physician to monitor the patient's colorectal cancer (CRC) risk over the course of their screening lifetime, especially for those who are aged 50 years or more. More...


The blood test does not require any advance preparation, only the collection of a small blood sample, and differs from other tests that often require fasting and other dietary restrictions and with those patients having to collect multiple fecal samples over the course of three days or more.

The test, known as the COLOGIC test, is based on the discovery that approximately nine out of ten patients with colorectal cancer are deficient in novel anticancer and anti-inflammatory metabolites in their blood. COLOGIC detects this deficiency to determine patient risk. The COLOGIC test has a sensitivity of 86% versus an average range of 35% to 61% for fecal occult blood test/fecal immunochemical test (FOBT/FIT). The specificity of the test is reportedly 90%.

Clinical support for COLOGIC includes four published papers outlining the science and clinical outcomes of a study involving 4,923 patients. The test measures levels of gastrointestinal tract acid-446 (GTA-446), a long-chain polyunsaturated fatty acid present in the serum. The CRC incidence rate in subjects undergoing colonoscopy with low GTA-446 levels was over six times higher than for subjects with normal GTA-446 levels and twice that of subjects with gastrointestinal symptoms.

The COLOGIC test was developed by Phenomenome Discoveries Inc., (Saskatoon, SK, Canada) and will provide an easily understood result on whether the individual has an elevated risk for colon cancer. Mario Castelli MD, a gastroenterologist, said, “Colorectal cancer is a completely preventable disease if we screen for it, and it gets more common as we get older, so that's why the recommendation is, usually starting at the age of 50, that everyone should be screened. This is a much simpler test. The patient just goes to the laboratory without any preparation, have a blood sample drawn and the results go to your physician within days.” It should be noted that COLOGIC test is not a substitute to colonoscopy. A positive test result should be followed up with a colonoscopy to confirm the presence of cancer.

Related Links:

Phenomenome Discoveries Inc.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.